Navigation Links
Gene therapy extends survival in large animal models of spinal muscular atrophy
Date:5/22/2014

New Rochelle, NY, May 22, 2014To make up for insufficient amounts of SMN protein, the cause of the inherited neuromuscular disease spinal muscular atrophy (SMA), researchers have successfully delivered a replacement SMN1 gene directly to the spinal cords of animal models of SMA. A new study demonstrating that enough copies of the SMN1 gene can be delivered to the spinal cord motor neurons to extend the survival of the treated animals is published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Human Gene Therapy website.

Marco Passini and coauthors from Genzyme (Framingham, MA), University of California San Francisco, Emory University School of Medicine (Atlanta, GA), and Georgetown University Medical Center (Washington, DC) used an adeno-associated viral vector as the delivery vehicle to transport copies of the SMN1 gene into motor neurons in the spinal cord via intrathecal delivery. They report on the effectiveness of restoring the levels of functional SMN protein in normal pig and non-human primate SMA models that would predict efficacy based on gene transfer with the same vector in an authentic mouse model of SMA in the article "Translational Fidelity of Intrathecal Delivery of Self-Complementary AAV9Survival Motor Neuron 1 for Spinal Muscular Atrophy."

"This is a very promising and thorough set of preclinical studies that supports rapid translation to the clinic," says James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.


'/>"/>

Contact: Kathryn Ruehle
kruehle@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1

Related medicine news :

1. The interruption of biological rhythms during chemotherapy worsen its side effects
2. First test of pluripotent stem cell therapy in monkeys is a success
3. Low-dose anticoagulation therapy can be used safely with new design mechanical heart valve
4. New agent may enhance effectiveness of radiotherapy
5. Novel target found for chemotherapy-resistant leukemia cells
6. A form of immune therapy might be effective for multiple myeloma
7. Therapy sought to reduce major risk from minor bleeding that can follow stroke
8. Drug therapy for allergy moves forward
9. Two-lock box delivers cancer therapy
10. WHI reports $37.1B economic return on combined hormone therapy clinical trial
11. Study finds family-based exposure therapy effective treatment for young children with OCD
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene therapy extends survival in large animal models of spinal muscular atrophy
(Date:1/19/2017)... ... ... WhoHaha , a digital media company dedicated to creating and delivering female-centric, comedic content, ... series that uses humor to highlight ways to improve heart health and overall well-being. ... movement, which is designed to inspire all Americans to make small changes that add ...
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. Andrew Lian-Jie ... fellowship trained Mohs and cosmetic surgeon. After extensive dermatology research training at the ... internship in internal medicine at the Emory University and dermatology training at the ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... for patients with sleep apnea and TMJ disorders. These conditions are quite common ... Dr. Rassouli provides personalized care to reduce the risk of these consequences and ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... asset protection and financial planning services to communities throughout eastern Georgia, is embarking ... against heart disease. , Heart disease kills more Americans every year than anything ...
(Date:1/19/2017)... ... January 19, 2017 , ... Creative ... Create Real Impact contest from Impact Teen Drivers and California Casualty. Entries from ... , Educational grants totaling $15,000 will be awarded for the best peer-to-peer ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor ... global anti-obesity drugs market is expected to grow at a ... and CAGR of 38.7% in the second half of the forecast ... 32.8% from 2016 to 2027. The market is estimated at $1,058 ... 2027. ...
(Date:1/19/2017)... 19, 2017  Sensus Healthcare, Inc. (NASDAQ: ... in the treatment of non-melanoma skin cancers and ... radiation therapy, today announced that it will report ... results on Thursday, February 2, 2017 after the market ... conference call with the investment community on Thursday, February ...
(Date:1/19/2017)... New Review of Safinamide ... Symptoms and Motor Complications in Mid- to Late-stage ... ... C Warren Olanow ... 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late Published ...
Breaking Medicine Technology: